{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"description":"Safety (number of adverse events and serious adverse events) after repeated doses of CAM2029 (assessment period from Day 0 to Day 84) and single dose Sandostatin LAR (assessment period Day -28 to Day 0)","groups":[{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks\n\noctreotide FluidCrystal® injection depot","id":"OG000","title":"CAM2029 10 mg q2w (Acromegaly)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly\n\noctreotide FluidCrystal® injection depot","id":"OG001","title":"CAM2029 20 mg q4w (Acromegaly)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks\n\noctreotide FluidCrystal® injection depot","id":"OG002","title":"CAM2029 10 mg q2w (NET)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly\n\noctreotide FluidCrystal® injection depot","id":"OG003","title":"CAM2029 20 mg q4w (NET)"},{"description":"Period day -28 to day 0 All acromegaly patients and all treatment groups","id":"OG004","title":"Sandostatin LAR (Acromegaly)"},{"description":"Period day-28 to 0 All NET patient and all treatment groups","id":"OG005","title":"Sandostain LAR (NET)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population (n=12). Patients treated with Sandostatin LAR Day -28 to 0 and CAM2029 (Day 0 to Day 84)","reportingStatus":"POSTED","timeFrame":"Day -28 to Day 84","title":"Number of Adverse Events and Serious Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}